Pulmonology Prior Authorization Automation

Klivira delivers robust pulmonology prior authorization automation, specifically designed to accelerate approvals for high-cost biologics and critical respiratory therapies.

Managing prior authorizations in pulmonology presents unique challenges, from the intricate step-therapy protocols for biologics to the recurring needs for home oxygen and respiratory devices. These complexities often lead to administrative burden, delays in patient care, and increased denial rates. Klivira's platform is engineered to address these specific bottlenecks, enhancing efficiency and improving patient access to necessary treatments.

High-Volume Prior Authorization Categories in Pulmonology

Pulmonology practices frequently encounter prior authorization requirements across a range of high-cost medications and durable medical equipment. These include biologics for severe asthma, specialty drugs for COPD and IPF, and essential respiratory support devices. Efficiently managing these diverse categories is critical for maintaining patient care continuity and optimizing revenue cycles.

Common PA-Triggering Treatments and Therapies

  • Asthma biologics: omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), tezepelumab (Tezspire) (Corpus: PA-triggering code categories)
  • COPD specialty drugs: ensifentrine (Ohtuvayre), and select triple-therapy inhalers like Trelegy and Breztri (Corpus: PA-triggering code categories)
  • IPF (idiopathic pulmonary fibrosis) antifibrotics: pirfenidone (Esbriet), nintedanib (Ofev) (Corpus: PA-triggering code categories)
  • Home oxygen, BiPAP/CPAP devices (Corpus: PA-triggering code categories)
  • Lung transplant evaluation and immunosuppression regimens (Corpus: PA-triggering code categories)
  • Pulmonary function testing

Navigating Complex Documentation and Guidelines

Pulmonology prior authorizations often demand adherence to specific clinical guidelines from organizations like the American Thoracic Society (ATS) (Corpus: ats-guidelines), Global Initiative for Chronic Obstructive Lung Disease (GOLD) (Corpus: gold-copd), and Global Initiative for Asthma (GINA) (Corpus: gina-asthma). For asthma biologics, this frequently includes detailed eosinophil counts, documentation of prior controller therapy at maximum dose, and a comprehensive exacerbation history. Klivira's platform streamlines the collection and submission of this critical data.

Addressing Common Prior Authorization Denial Reasons

Denials in pulmonology often stem from specific clinical criteria not being met or adequately documented. These can include a failure to demonstrate adherence to payer-mandated step-therapy protocols for asthma biologics, insufficient eosinophil-count thresholds for IL-5-targeting agents, or a lack of documented conservative therapy for IPF antifibrotics. Understanding and proactively addressing these common pitfalls is key to improving approval rates.

Klivira's Solution for Pulmonology Prior Authorization Automation

Klivira integrates seamlessly into your existing EMR workflow, providing an intelligent automation layer specifically tailored for pulmonology. Our platform incorporates GINA/GOLD/ATS-aware step-therapy logic and automates the documentation of critical data points such as eosinophil counts (Corpus: Klivira's approach). We also streamline re-authorization workflows for biologics, ensuring continuous patient access to vital therapies. This targeted approach reduces manual effort and accelerates time to approval.

Frequently asked questions

How does Klivira handle the specific step-therapy requirements for asthma biologics?

Klivira's platform incorporates GINA/GOLD/ATS-aware step-therapy logic (Corpus: Klivira's approach) to guide your team through payer-specific requirements. It helps identify and document the necessary prior controller therapies and exacerbation history, ensuring compliance with common payer policies.

Can Klivira automate the documentation of eosinophil counts for biologics?

Yes, Klivira automates the extraction and documentation of eosinophil counts, which are critical for many IL-5-targeting biologics (Corpus: Klivira's approach). This reduces manual data entry errors and ensures that this key clinical criterion is accurately presented in the prior authorization submission.

Does Klivira assist with re-authorizations for ongoing pulmonology treatments?

Absolutely. Klivira includes specific workflows for managing re-authorizations, particularly for long-term therapies like asthma biologics (Corpus: Klivira's approach). The system can track authorization expiry dates and proactively initiate the re-authorization process, minimizing gaps in patient care.

How does Klivira integrate with our existing EMR for pulmonology PA processes?

Klivira is designed for seamless integration with leading EMR systems via standard protocols like SMART on FHIR. This allows for direct data exchange, pulling necessary clinical documentation and patient demographics directly from the EMR to populate prior authorization requests, reducing duplicate data entry and improving accuracy.

What types of pulmonology services beyond biologics can Klivira automate PA for?

Beyond biologics, Klivira can automate prior authorizations for a wide range of pulmonology services. This includes home oxygen, BiPAP/CPAP devices, pulmonary function testing, and evaluations for lung transplant, addressing the diverse needs of a comprehensive pulmonology practice.

Related coverage

Pulmonology prior auth workflows

Pulmonology prior auth coverage by state

Pulmonology prior authorization by drug

Pulmonology prior authorization by procedure

Ready to automate prior auth for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo